Jazz Pharmaceuticals plc (J7Z.F)
| Previous close | 100.80 |
| Open | 99.28 |
| Bid | 99.04 x 1700 |
| Ask | 99.64 x 1700 |
| Day's range | 99.16 - 99.52 |
| 52-week range | 95.18 - 134.35 |
| Volume | |
| Avg. volume | 27 |
| Market cap | 6.276B |
| Beta (5Y monthly) | 0.62 |
| PE ratio (TTM) | 22.07 |
| EPS (TTM) | 4.51 |
| Earnings date | 06 Aug 2024 - 14 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 208.50 |
Investor's Business DailyJazz Dives — But Key Rival Praxis Surges — On Essential Tremor Drug Failure
Jazz stock toppled Thursday — but shares of key rival Praxis surged — after its essential tremor drug failed in midstage testing.
PR NewswireJazz Pharmaceuticals Provides Update on Phase 2b Trial of Investigational Suvecaltamide (JZP385) in Essential Tremor
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 2b clinical trial (NCT05122650) evaluating the efficacy and safety of suvecaltamide (JZP385), an investigational, highly selective and state-dependent modulator of T-type calcium channels, in adult patients with essential tremor (ET). Suvecaltamide did not achieve statistical significance at 30mg versus placebo on the primary endpoint of change from baseline to week 12 on the Essential Tremor Rating Assessmen
- PR Newswire
Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced long-term follow-up results, including the first-ever overall survival (OS) findings, from the Phase 2b HERIZON-BTC-01 clinical trial of zanidatamab in previously treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC). These data will be featured at the American Society of Clinical Oncology (ASCO) Annual Meeting in a poster presentation during the Gastrointestinal Cancer – Gastroesophageal, Pancreati
